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Abstract: Background
Transport And Golgi Organization protein 2 (TANGO2) deficiency has recently been
identified as a rare metabolic disorder with a distinct clinical and biochemical
phenotype of recurrent metabolic crises, hypoglycemia, lactic acidosis,
rhabdomyolysis, arrhythmias and encephalopathy with cognitive decline.
Patient and methods
We report 9 subjects from 7 independent families carrying TANGO2 mutations that
presented with clinical features of TANGO2 deficiency. We studied muscle histology,
respiratory chain enzyme activities in skeletal muscle and proteomic signature of
fibroblasts.
Results
All 9 subjects carried autosomal recessive TANGO2 mutations. Two carried the
reported deletion of exons 3-9, one homozygous, one heterozygous with a 22q11.21
microdeletion inherited in trans. The other subjects carried three novel homozygous
(c.262C>T/p.Arg88*; c.220A>C/p.Thr74Pro; c.380+1G>A), and two further novel
heterozygous (c.6_9del/p.Phe6del); c.11-13delTCT/p.Phe5del mutations. Immunoblot
analysis detected a significant decrease of TANGO2 protein. Muscle histology showed
mild variation of fiber diameter, no ragged-red/COX-negative fibres and a defect of
multiple respiratory chain enzymes and coenzyme Q10 in two cases, suggesting a
possible secondary defect of oxidative phosphorylation. Proteomic analysis in
fibroblasts revealed significant changes in components of the mitochondrial fatty acid
oxidation, plasma membrane, ER-Golgi network and secretory pathways.
Conclusions
Clinical presentation of TANGO2 mutations is homogeneous and clinically
recognizable. The hemizygous mutations in two patients suggest that some mutations
leading to allele loss are difficult to detect. A combined defect of the respiratory chain
enzymes and coenzyme Q10 with altered levels of several membrane proteins
provides molecular insights into the underlying pathophysiology and may guide rational
new therapeutic interventions.
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 Dear Dr. Verena Peters, 
 
We wish to submit the revised version of our manuscript entitled “Clinical presentation and 
proteomic signature of patients with TANGO2 mutations” (#BOLI-D-19-00033). 
Thanks a lot for pointing out the question about “hemizygosity” in the abstract. We have 
changed it for “heterozygous”.  
 
Yours sincerely, 
Rita Horvath 
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Abstract 
Background: Transport And Golgi Organization protein 2 (TANGO2) deficiency has recently 
been identified as a rare metabolic disorder with a distinct clinical and biochemical phenotype 
of recurrent metabolic crises, hypoglycemia, lactic acidosis, rhabdomyolysis, arrhythmias and 
encephalopathy with cognitive decline.  
Patient and methods: We report 9 subjects from 7 independent families and we studied muscle 
histology, respiratory chain enzyme activities in skeletal muscle and proteomic signature of 
fibroblasts.  
Results: All 9 subjects carried autosomal recessive TANGO2 mutations. Two carried the 
reported deletion of exons 3-9, one homozygous, one heterozygous with a 22q11.21 
microdeletion inherited in trans. The other subjects carried three novel homozygous 
(c.262C>T/p.Arg88*; c.220A>C/p.Thr74Pro; c.380+1G>A), and two further novel 
heterozygous (c.6_9del/p.Phe6del); c.11-13delTCT/p.Phe5del mutations. Immunoblot analysis 
detected a significant decrease of TANGO2 protein. Muscle histology showed mild variation 
of fiber diameter, no ragged-red/cytochrome c oxidase (COX)-negative fibres and a defect of 
multiple respiratory chain enzymes and coenzyme Q10 (CoQ10) in two cases, suggesting a 
possible secondary defect of oxidative phosphorylation. Proteomic analysis in fibroblasts 
revealed significant changes in components of the mitochondrial fatty acid oxidation, plasma 
membrane, ER-Golgi network and secretory pathways.  
Conclusions: Clinical presentation of TANGO2 mutations is homogeneous and clinically 
recognizable. The hemizygous mutations in two patients suggest that some mutations leading 
to allele loss are difficult to detect. A combined defect of the respiratory chain enzymes and 
CoQ10 with altered levels of several membrane proteins provides molecular insights into the 
underlying pathophysiology and may guide rational new therapeutic interventions. 
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Synopsis: Here we report genetic and biochemical results of 9 new patients from 7 families 
with TANGO2 deficiency including proteomic analysis data that provided novel molecular 
insights into the disease mechanism and revealed a rationale for new therapeutic interventions. 
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Background 
The family of TANGO proteins plays a crucial role in the interaction of the Golgi apparatus 
and the endoplasmic reticulum (ER). Bi-allelic TANGO2 (NM_152906.5) mutations have been 
identified as a cause of a pediatric disease with multi-organ involvement (Kremer et al, 2016; 
Lalani et al, 2016). TANGO2 was first described in a genome-wide RNA-mediated interference 
screen in Drosophila (Maynard et al, 2008). TANGO2 is localized to the Golgi and the 
cytoplasm. Its depletion leads to the fusion of Golgi membranes with the ER (Bard et al, 2006). 
Consequently, increased ER stress was postulated to be a contributing factor to the disease 
mechanism of TANGO2 deficiency (Kremer et al, 2016). A total of 29 cases have been reported 
to date (Supplementary Tables 1 & 2). The most frequent mutation in patients with European 
ancestry (minor allele frequency (MAF) 0.0013) is a 34 kB deletion of exons 3-9, present in 17 
patients. This change was present in one additional patient who also carried a de novo 22q11.21 
deletion inherited in trans. A missense mutation (c.460G>A/p.Gly154Arg) has a 0.0026 MAF 
in the Hispanic/Latino population and was present in 6 of the reported patients (Kremer et al, 
2016; Lalani et al, 2018). Other mutations are rare and uniquely identified within single 
families. Independent of the underlying mutation, all reported cases show a remarkably similar 
neurological phenotype in combination with severe recurrent metabolic crises resulting in 
rhabdomyolysis, severe encephalopathy and life-threatening arrhythmias. The age of onset 
varied from 4 months to 8 years and in most cases neurological symptoms were present before 
the first critical metabolic derangement. Biochemical findings during metabolic crisis included 
lactic acidosis, hypoglycemia, ketonuria - similar to mitochondrial diseases. However, the 
presence of rhabdomyolysis with very high creatine kinase (CK) levels with non-specific 
increase of acylcarnitines and dicarboxylic acids were hallmarks of TANGO2 deficiency 
(Kremer et al, 2016; Lalani et al, 2018).  
To date, very little is known about the function of the TANGO2 protein and its role in metabolic 
decompensation. However, the clinical presentation and metabolic changes raised the 
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possibility that mitochondrial impairment and an increase of ER stress may be underlying 
pathophysiological factors (Bard et al, 2006; Lalani et al, 2018). Notably, both, the human and 
the mouse orthologue of TANGO2 (NM_152906.6), T10 (NM_138583.2) (Maynard et al, 2008; 
Napoli et al, 2015) have a mitochondrial targeting sequence suggesting mitochondrial 
localization.  
To further elucidate the clinical presentation and pathophysiological background of the disease 
we report nine new patients with studies on the proteomic signature of TANGO2-deficient 
fibroblasts. 
 
Case reports 
We report nine novel TANGO2 cases - four male and five female patients from seven different 
families, summarized in Table 1. All patients presented with a very similar clinical phenotype 
of progressive neurodevelopmental decline and recurrent metabolic crisis, combined with 
distinct biochemical findings. Five out of seven patients showed no complications during 
pregnancy, delivery or neonatal period, although two individuals (subject 1 and subject 3.2) 
were small for gestational age and presented with severe microcephaly at birth (head 
circumference 31 cm, SDS -2, 9 and 32 cm, SDS -2,8 respectively). Expanded newborn 
screening for inherited metabolic diseases was normal in 4 out of 7 cases. The first symptoms 
occurred before 2 years of age when psychomotor retardation became evident in all patients, 
commonly associated with mild generalized muscular hypotonia, difficulties or inability to 
ambulate and cognitive impairment with poor or absent speech development.  
All patients had metabolic encephalomyopathic crises between 6 months (subject 1) and 9 
years (subject 2.2) of age. In the intervals the patients achieved a stable metabolic status with 
nearly normalized laboratory values and a good general condition. However, a progressive 
neurological decline with severe global psychomotor retardation was present in most patients 
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except for subject 2.2, who only had moderate intellectual disability with learning difficulties, 
requiring special education. Most reported subjects developed epilepsy and progressive ataxia 
with dysarthric speech, inability to walk and spasticity. Brain MRI was abnormal, showing a 
mild global brain atrophy in two patients (subjects 1 and 4) and microcephaly in subject 3.2 
(Supplementary Figure 1).  
The metabolic crises were characterized by an acute onset, often triggered by infection or 
physical stress. Serum biochemistry testing showed a very similar pattern in all cases with very 
high (419 - 400,000 U/l) creatine kinase (CK) levels, lactic acidosis, elevated transaminases 
and hyperammonemia. Hypoglycemia was documented in two patients (subject 1 and subject 
6) and non-specific elevation of acylcarnitines and dicarboxylic acids in four patients (subject 
1, 4, 5 and 6) suggestive of generalized energy deficiency. Ketonuria and thyroid stimulating 
hormone (TSH) elevation was present in 8/9 cases. TSH elevation was treated with L-Thyroxin 
in subject 2.1, 2.2, 3.1, 3.2, 4 and 6. Cerebrospinal fluid (CSF) analysis did not reveal signs of 
metabolic derangement in any patients.  
In line with the characteristic biochemical alterations during metabolic crises, all patients 
showed overlapping clinical presentations with repeated bouts of massive rhabdomyolysis, 
hepatopathy and often severe encephalopathy with unresponsiveness and generalized seizures, 
requiring ICU treatment. Some of our reported patients developed life-threatening arrhythmias 
(Torsade de Pointes) on the basis of a Long-QT-Syndrome. Malignant arrhythmias led to 
premature death in 3 cases: subject 2.2 at the age of twelve years after she had experienced 
several encephalomyopathic episodes, subject 3.2 at the age of five years without any prior 
metabolic derangements and despite propranolol therapy and subject 4 at the age of eight years. 
Subject 2.1) survived various arrhythmic episodes, developed left ventricular failure and died 
because of a bacterial superinfection resulting in multi-organ failure at the age of 7 years. 
Subject 3.1, regardless of continuous propranolol therapy, developed repetitive life threatening 
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arrhythmias which he survived.  Subjects 1, 4, 5 and 7 showed a long QT syndrome in ECG, 
and subject 4 died at the age of 8 years due to cardiac complications. Hypertrophic 
cardiomyopathy was observed in subject 5.  
Autopsy of subject 2.1 and 2.2 revealed diffuse oedema of the CNS, myocardial softening, with 
dilatation of cavities. The histological examination showed mild disarray of overall architecture 
of myocytes with hypertrophy and mild interstitial fibrosis. In skeletal muscle, necrosis was 
present, in line with repeated episodes of rhabdomyolysis. In liver, hepatocyte cytoplasm 
appeared granular with few fat vacuoles in subject 2.1 without abnormal glycogen storage 
(Supplementary Figure 2).  
The clinical phenotype and unique biochemical profile were highly suggestive of a metabolic 
muscle disease, therefore muscle biopsy has been performed in seven cases from six different 
families (subject 1, 2.1, 2.2., 3.1, 4, 5, 7). Following the working diagnosis of an underlying 
metabolic myopathy (potentially mitochondrial), anabolizing management was performed 
during the acute crises leading to a slow stabilisation of the metabolic derangement in the 
majority of episodes. The reported patients received supplemental therapy consisting of 
riboflavin (vitamin B2), carnitine and thiamine (vitamin B1) (subject 1), carnitine, vitamin A/ 
E/ B2 (subject 2.1, 2.2), or vitamin B1 and carnitine respectively (subject 3.1 and 3.2). This 
supplemental therapy was continued in the interval but could not prevent repetitive metabolic 
decompensations in subject 1, 2.1, 2.2. and 3.1. The pharmaceutical regimen was expanded 
with Q10 substitution for subject 1 and subject 3.1, with regard to reduced CoQ10 levels, which 
helped prevent further metabolic derangements to date. Subject 4 did not receive any specific 
therapy. 
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Methods 
Genetic studies 
Whole exome sequencing (WES) was applied in subjects 1, 3.1, 3.2 and 4. Whole genome 
sequencing (WGS) was performed in subjects 2.1 and 2.2 (see Supplementary Materials). In 
subjects 5, 6 and 7, targeted sequencing of the TANGO2 gene (NM_152906.5) was undertaken 
using BigDye Terminator v3.1 Sanger sequencing on an ABI3130xl.  
 
Muscle histology and biochemistry  
Muscle histology and spectrophotometric analysis of the respiratory chain enzymes was 
performed as previously described (Kirby et al, 2007; Prestel et al, 2008). Muscle CoQ10 
analysis was done by HPLC with electrochemical detection, as reported (Rodríguez-Aguilera 
et al, 2017) 
 
Cell culture  
Primary human fibroblasts from patients and controls were cultured in minimum essential 
media (MEM) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, 2mM 
L-glutamine, 1x non-essential amino acids, 1x minimum essential medium vitamins, 1mM 
sodium pyruvate, 50µg/ml uridine (ThermoFisher Scientific), at 37°C, in a humidified 5% CO2 
atmosphere. 
 
Immunoblotting 
Immunoblotting was performed as described previously (Bartsakoulia et al, 2018).  Primary 
antibodies were Anti-C22orf25 antibody (Abcam, ab87576), GAPDH antibody (FL-335) 
(Santa Cruz, sc-25778), alpha tubulin (Abcam, ab7291), Anti-VDAC1 (Abcam, ab14734). 
Oxidative phosphorylation (OXPHOS) proteins were probed using Total OXPHOS Human WB 
Antibody Cocktail (Abcam, ab110411) in subjects 1, 2.1 2.2, 4, 6. In Family 2 proteins were 
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detected fluorescently using the Total OXPHOS Antibody Cocktail and Anti-VDAC1/Porin 
antibody (Abcam, ab154856) using fluorescently labelled secondary antibodies (Licor IRDye 
800CW anti-rabbit, 926-32211 and Licor IRDYE 680RD anti-mouse, 925-68070) and 
visualised on a Licor Odyssey® CLx.  
 
Golgi trafficking 
Golgi- apparatus (GA)-ER retrograde transport was analyzed by immunofluorescence using 
anti-GM130 antibody followed by microscopy in fibroblasts of subject 2.1 and 2.2 as well as 
control cells. To monitor GA-ER retrograde vesicle transport the number of cells with 
assembled GA was counted at different time points upon Brefeldin A (BFA) treatment, an 
inhibitor of the ER– Golgi anterograde transport (Jackson et al, 2000). For each experimental 
condition 100-125 cells were counted. The results were expressed as percentage of cells with 
assembled GA. 
 
Proteomic analysis  
In total six samples (three TANGO2-patient derived fibroblasts (subjects 1, 3.1 and 4) and 
three control fibroblast lines) were processed independently. Sample preparation was 
performed using filter-aided sample preparation (FASP) as described previously (Wisniewski, 
2016). Data analysis of the acquired label free quantitative MS was performed using the 
Progenesis LC-MS software from Nonlinear Dynamics (Newcastle upon Tyne, U.K.) (see 
Figure 2 and supplementary material).  
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Results 
Genetic studies  
In subject 1 mutation analysis of several candidate genes was negative including POLG and 
the known CoQ10 biosynthesis genes. WES identified a homozygous nonsense mutation 
(c.262C>T, p.Arg88*) in the TANGO2 (NM_152906.5) gene (Supplementary Figure 3). This 
variant is predicted to result in a premature stop codon and not present in ExAc or Bravo 
databases. In subject 2.1 and 2.2 focussed single gene analysis comprised NGS panel for genes 
associated with channelopathies, Long QT syndrome, DMD, LPIN1 and RYR1 were negative. 
WGS revealed a heterozygous TANGO2 mutation (c.11_13delTCT, p.Phe5del) and a putative 
gene deletion causing a loss in the second allele, which could not be detected by analysis of 
structural variation. Subject 3 and 3.1. are homozygous carriers of the mutation c.380+1G>A, 
affecting the exon 5 essential splice site (Supplementary Figure 3). In subject 4 targeted 
sequencing of DMD and LPIN1 were normal and no mitochondrial deletions were detected. 
After the first TANGO2 mutations had been published, WES results were re-evaluated, 
detecting a novel homozygous missense mutation in TANGO2: c.220A>C, p.Thr74Pro 
(Supplementary Figure 3). In subject 5 no pathogenic mutations were detected in ACADVL, 
ACAD9 or LPIN1. WES initially revealed no clear cause for these symptoms. Targeted 
sequencing of the TANGO2 gene revealed a hemizygous deletion of exons 3-9, proven to be 
inherited from her father. The second mutation, which resulted in allele loss could not be 
identified. Subject 6 underwent targeted Sanger sequencing of the coding regions of TANGO2 
revealing a homozygous in-frame deletion c.6_9del, p.Phe6del. In Subject 7, a heterozygous 
mutation in VLCAD was detected but not considered relevant as VLCAD enzyme activity was 
normal in the cultured fibroblasts. Targeted sequencing of the TANGO2 gene revealed a 
homozygous deletion of exons 3-9. 
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Muscle histology and biochemistry 
Muscle histology and histochemistry of subjects 1, 2.1, 2.2, 3.1 and 4 revealed a mild variation 
of fiber diameter but no ragged-red fibers or COX-deficient fibers. All samples showed a 
variable extent of regenerative and degenerative changes including necrosis, consistent with the 
history of rhabdomyolysis. Muscle histology for subject 1 shows mild variation of fibre 
diameters in the H&E staining (a) and no signs of mitochondrial accumulation in trichrome 
staining (b) (Supplementary Figure 2). In subject 4, there was a significant type 2 fiber 
predominance, up to 80%. All samples were taken in a symptom-free interval without acute 
rhabdomyolysis. In subject 1 electron microscopic examination was performed and did not 
show any relevant alterations of mitochondrial morphology. In subject 5, muscle biopsy 
analysis revealed significant lipid accumulation similar to defects of fatty acid oxidation, which 
is a non-specific finding. No muscle biopsy was taken from subject 6. The muscle biopsy from 
subject 7 showed evidence of previous muscle fibre degeneration and necrosis, likely due to 
repeated episodes of muscle fibre breakdown with rhabdomyolysis. Electron microscopy results 
did reveal large areas of degenerative and regenerative fibers with clumping of mitochondria 
and some mitochondria appearing enlarged, with no inclusions observed and without typical 
changes of primary mitochondrial dysfunction.  
OXPHOS activities were measured in several cases, although no uniform pattern of changes 
was identified across all patients (Supplementary Table 3). In subject 1 biochemical assessment 
of the respiratory chain enzyme activities revealed a combined decrease involving complexes I 
and IV, with an associated CoQ10 deficiency (Supplementary Table 3). A second muscle biopsy 
taken a few years later confirmed these earlier findings (results not shown). Subject 2 showed 
multiple deficiencies in mitochondrial respiratory chain enzyme activities in muscle, relative to 
an observed increased citrate synthase activity while investigations in fibroblasts were normal. 
CoQ10 in muscle was decreased. In subject 4 muscle respiratory chain activities were all 
normal, although western blot analysis of the OXPHOS complexes revealed a subtle reduction 
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in important subunits of complexes II, III, IV (Figure 1B). In subject 3.1 and subject 3.2 
respiratory chain activity was not analysed. Respiratory chain enzyme activities in subjects 5 
and 7 were normal. 
 
Immunoblotting 
In subject 1 TANGO2 protein levels in primary fibroblasts were markedly reduced when 
compared to two different controls, although we still detected a very slight residual band, which 
is unexpected in the case of a homozygous nonsense mutation (Figure 1). In subject 2.1 we 
found similar results with markedly reduced TANGO2 protein levels as well as in subject 4 
and subject 6 with an underlying missense mutation (Figure 1A).  
Western blot analysis of total protein lysate from fibroblasts of subject 1 showed a significant 
decrease in steady state levels of OXPHOS components of complex I (p=0.034812) and 
complex III (p=0.003068) when compared to two control fibroblast cell lines. Subject 4 
presented a reduction in OXPHOS complexes II, III, IV (Figure 1B). Whereas western blot 
analysis from subject 2.1 and 2.2 showed a non-specific increase of all OXPHOS complexes 
as a possible compensatory reaction. The defect of OXPHOS complexes was not linked to any 
specific TANGO2 genotype. 
 
Golgi trafficking 
To determine whether the functionality of the GA-ER retrograde vesicle transport could be 
affected in TANGO2 deficient cells we monitored the disassembly of the GA upon BFA 
treatment in subjects 2.1.and 2.2. Our results showed that 5-10 minutes after addition of BFA 
to the culture medium the GA was disassembled in the 55 per cent of the control cells. In 
contrast, in TANGO2 patients the amount of cells with disassembled GA at the same time points 
was reduced to 33 per cent (Figure 3). Although 60 minutes after BFA treatment all cells 
showed disassembled GA in both control and patient cells, the delayed disassembly detected at 
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earlier time points is suggestive of a possible impairment in the retrograde GA-ER trafficking 
in TANGO2 patient fibroblasts (Figure 3).  
 
Proteomic signature of fibroblasts carrying autosomal recessive TANGO2 mutations 
Here, we analyzed the proteomic signature of our patients` fibroblasts (subjects 1, 3.1 and 4) 
using a label-free approach (Figure 2, (Roos et al, 2018). We found that 2.3% of the quantified 
proteins (55 out of 2355) were significantly differentially abundant upon TANGO2 mutations 
in fibroblasts: 16 (29%) of these proteins were increased and 39 (71%) decreased. The affected 
proteins are localized in the ER-Golgi network (e.g. cell migration-inducing and hyaluronan-
binding protein CEMIP, protein transport protein Sec23B), the secretory pathway (e.g. 
peroxidasin homolog PXDN, serine protease HTRA1), the plasma membrane (e.g. gap junction 
protein alpha-1 CXA1, major prion protein PRIO, sodium dependent phosphate transporter 2 
S20A2) and in mitochondria (e.g. aldehyde dehydrogenase 4 AL4A1) (Figure 2). In addition, 
significant changes were detected in proteins involved in fatty acid oxidation (e.g. 
mitochondrial carnitine/acylcarnitine carrier protein MCAT, Fatty aldehyde dehydrogenase 
AL3A2) and amino acid metabolism (e.g. methylmalonate-semialdehyde dehydrogenase 
MMSA). SLC25A20, encoding a mitochondrial carnitine/acylcarnitine carrier protein was 
decreased in TANGO2-patient derived fibroblasts. For an overview on the regulated proteins 
and proposed functions, see Supplementary Table 4. Interestingly, protein levels for OXPHOS 
complexes I, III, IV and V were not significantly altered in fibroblasts, whereas complex II and 
TANGO2 protein were not detected by proteomic analysis in normal and mutant fibroblasts 
despite being detectable by Western blotting. 
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Discussion 
We report nine children presenting during early childhood with severe psychomotor 
developmental delay, refractory seizures and recurrent metabolic crises with lactic acidosis, 
accompanied by rhabdomyolysis, cardiac arrhythmias and encephalopathy. Next generation 
sequencing revealed five novel mutations, and we show that 4 mutations result in a relevant 
reduction or dysfunction of TANGO2 protein in fibroblasts, suggesting a loss of function 
disease mechanism.   
Previous studies utilizing fibroblasts derived from patients with TANGO2 mutations suggested 
ER stress and altered Golgi volume density and noted defective mitochondrial fatty acid 
oxidation (Kremer et al, 2016; Lalani et al, 2018). In two of our cases biochemical investigation 
revealed a reduced activity of different OXPHOS complexes in skeletal muscle (subject 1, 2.1) 
and normal OXPHOS activity in subject 4 (Supplementary Table 3). These findings are 
underscored by Western blot analysis of OXPHOS complex subunits showing significant 
reduction of complexes I and III in subject 1 and II, III, IV in subject 4 respectively (Figure 
1). Moreover, respiratory chain analyses showed CoQ10 deficiency in subject 1 and 2.1, while 
in the other reported subjects CoQ10 levels were not assessed. This CoQ10 reduction might be a 
secondary effect of the fatty acid oxidation impairment, similar to CoQ10 deficiency in multiple 
acyl-CoA dehydrogenase deficiency (MADD) (Gempel et al, 2007; Horvath, 2012). We 
initiated a CoQ10 and riboflavin supplementation in subjects 1 and 3.1 which resulted in clinical 
improvement and stabilization without any further metabolic crisis up until now, however 
assessing treatment with CoQ10 and measuring CoQ10 in additional patients is needed before 
our findings can be generalized. 
To date a total of 29 patients have been reported with bi-allelic TANGO2 mutations prior to this 
publication, all of which show a strikingly similar clinical phenotype. However, the 
biochemical phenotype is more variable. Except for an isolated mild reduction of complex I in 
one case (Kremer et al, 2016) the majority of the reported cases showed essentially normal 
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mitochondrial studies (Lalani et al, 2016) without clear respiratory chain dysfunction (15 out 
of 18 cases in which mitochondrial studies were performed, Supplementary Table 1). We 
performed proteomic profiling in fibroblasts, which indicated altered fatty acid oxidation, folic 
acid and pyrimidine metabolism in mitochondria (Wang, 2016). Impaired fatty acid oxidation 
was suggested by decrease of fatty aldehyde dehydrogenases (ALDH3A2, ALDH4A1, 
ALDH6A1; Baumgartner et al, 2005) and SLC25A20, encoding a mitochondrial 
carnitine/acylcarnitine carrier protein (Yan et al, 2017; Dines et al, 2018). Mutations in these 
genes lead to severe neurological abnormalities, developmental delay, cardiomyopathy, 
arrhythmias, skeletal muscle damage, liver dysfunction and episodes of life-threatening coma 
(Chambliss et al, 2000; Marcadier et al, 2013), many of these clinical findings are also present 
in TANGO2-deficient patients.  
Our proteomics results underline the impaired function of the protein processing machinery 
(Figure 2, Supplemental Table 4) as earlier described (Bard et al, 2006), and Golgi trafficking 
(Figure 3). In addition, the proteomic signature of TANGO2-mutant fibroblasts suggests an 
effect of the perturbed ER-Golgi system on target proteins (HTRA1, ITA1, ITA3, NCAM1, 
NEGR1, NTRI, PRIO, S20A2 and SYNP2). SYNP2 modulates F-actin networks (Kai & 
Duncan, 2013) and may contribute to skeletal muscle vulnerability and rhabdomyolysis in 
TANGO2 deficient patients. SDC3 organizes cell shape through actin cytoskeleton and 
regulates adult myogenesis (Pisconti et al, 2010), MYLK acts as a calcium/calmodulin-
dependent myosin light chain kinase and CAVN2 plays an important role in caveolar biogenesis 
and morphology. Caveolinopathy, a muscle disease based on mutations in Caveolin-3 can also 
present with muscle pain and rhabdomyolysis (Scalco et al, 2016), clinical manifestations in 
TANGO2-patients. The TANGO2-related cardiac phenotype is suggested by decrease of 
CXA1/CX43/GJA1 (Boengler & Schulz, 2017). Thus, our data indicate that mitochondrial and 
ER-Golgi function along with proper processing of secreted and plasma membrane proteins and 
fatty acid oxidation are predominantly affected by loss of functional TANGO2, highlighting 
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these processes as relevant for TANGO2 pathophysiology and most likely for TANGO2-
dependent disease manifestation. 
Taken together, proteomic signature of TANGO2-patient derived fibroblasts suggests new 
clues into the underlying pathophysiology providing a rational for future targeted therapy. 
Avoidance of typical precipitants (catabolic stress, especially during infection, trauma, 
vomiting) is recommended, although metabolic derangement did also occur in some patients 
without any identifiable trigger. Anabolizing management, treatment with vitamin B1, B2 and 
carnitine resulted in stabilization of metabolic crises in the reported patients, together with 
consequent treatment of organic complications (e.g. hyperammonemia, seizures, cardiac 
arrhythmias). Two of the reported subjects additionally received CoQ10 and did not suffer any 
further metabolic derangements to date. This highlights that in addition to the impairment of 
ER-Golgi, alterations of mitochondrial fatty acid oxidation, respiratory chain and amino acid 
pathways significantly contribute to the clinical presentations of TANGO2 deficiency. 
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Legends for Figures and Table 
Figure 1 
A) Immunoblotting for TANGO2 protein in control fibroblasts (C) and patient fibroblasts (P) 
in Families 1, 2 and 4. In Family 6, TANGO2 protein levels in muscle lysates of 2 controls and 
2 patients. Western blotting was performed in triplicates. B) Western blot analysis of OXPHOS 
complex subunits performed in total protein lysates from primary fibroblasts in the patients in 
Families 1 and 2, and in muscle lysates from patients and controls in Family 4.  
 
Figure 2 
Proteomic profiling of patient derived fibroblasts: A) Proteomic workflow applied to identify 
the proteins affected by the TANGO2-deficiency in fibroblasts. B) Volcano-plot of proteomic 
findings. Red dots represent proteins showing a statistically significant decrease, whereas green 
dots represent proteins with a statistically significant increase in abundance. C) Subcellular 
distribution of affected proteins. 
 
Figure 3 
Golgi apparatus (GA) -to-endoplasmic reticulum (ER) retrograde membrane flow. A) 
Immunofluorescence using anti-GM130 antibody followed by microscopy in TANGO2 patient 
fibroblasts (subject 2.2) and control cells. B) To monitor GA-ER retrograde vesicle transport 
the number of assembled GA at different time points upon Brefeldin (BFA) treatment (in 
percent) in both subjects (subject 2.1 and 2.2) and controls. C) Mean number of assembled GA 
at different time points upon Brefeldin (BFA) treatment (in percent) and error. 5 and 10 minutes 
after BFA addition to the culture medium a reduction of around 20 per cent in the amount of 
cells with assembled GA were observed in both patients compared to control cells. 
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Table legends 
Table 1: Clinical and diagnostic features in the presented subjects  
 
Legends for Supplementary Figures and Tables 
Supplementary Figure 1: Brain MRI in subject 1 at 6 months, 3 weeks after her first 
metabolic crisis had occured (A, B) and 6 years (C) of age, during a symptom-free interval. 
A) T2: Flair with multifocal diffusion restrictions accentuated in the left parieto-occipital 
regions. B) T1: deficient myelinization of the adjacent u-fibres. Widening of the inner and outer 
CSF spaces. C) T2: progressive widening of the inner and outer CSF spaces. Multifocal cystic 
lesions.  
 
Supplementary Figure 2: Muscle Biopsy and necropsy findings  
A) Muscle Biopsy in subject 1 at 6 months of age. a) Hematoxylin & Eosin (H&E) staining 
detected mild variation of fibre diameters; b) COX activity was normal; c) Trichrome staining 
was normal and did not detect signs of mitochondrial accumulation (no ragged red fibres). B) 
Autopsy findings at age 12 years: a) H&E staining in heart muscle (subject 2.2) showed mild 
disarray of the overall architecture of the myocytes with hypertrophy and a mild interstitial 
fibrosis. b) H&E stain in liver (subject 2.1) showed hepatocytes arranged in plates and the 
hepatocytes display polygonal morphology with well-defined borders. Hepatocyte cytoplasm 
appears granular and clear with few fat vacuoles in subject 2.1 (black arrows). Absence of portal 
or porto-portal fibrosis.  
 
Supplementary Figure 3 
Pedigrees and Sanger sequencing electropherograms for index cases and parental samples, 
where available, for Families 1, 2, 3 and 6. 
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Supplementary Table 1: Reported mutations in individuals with bi-allelic TANGO2 
mutations (1,2) 
Supplementary Table 2: Clinical and diagnostic features in the presented subjects  
Supplementary Table 3: Respiratory chain activity in skeletal muscle 
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Tables 
 
Table 1 Clinical and diagnostic features of subjects in this study  
Key: y: years; m: months; ECG: echocardiogram; EPS: extrapyramidal motor signs; ALT: alanine aminotransferase; AST: 
aspartate transaminase; CK: creatine kinase; TSH: thyroid stimulating hormone; Hom: homozygous 
Clinical features Subject 1 
Family 1 
 
Subject 
2.1 
Family 
2 
Subject 
2.2 
Family 2 
Subject 
3.1 
Family 3 
Subject 
3.2 
Family 3 
Subject 4 
Family 4 
Subject 5 
Family 5 
Subject 6 
Family 6 
Subject 7 
Family 7 
Sex female female female male male male female female male 
Consanguineous yes no no yes yes yes no yes no 
Ethnicity Caucasian Hispani
c 
Hispanic Caucasian Caucasian Arab Caucasian Afghan Caucasian 
Age of onset 6m 1 y 2 y 2 y 1 y. 2 y <1 y 6 m 13 m 
Developmental 
delay at onset 
severe severe mild moderate moderate moderate moderate mild/ 
moderate 
mild 
Recurrent 
metabolic crises  
(age at first event) 
yes (6 m) yes (5 y) yes (9 y) yes (2 y) no   yes (2 y) yes (5 y) yes (6 m) 
normal at 
age 2 y 
yes (13 m) 
ECG changes/ 
Cardiac 
Arrhythmias 
(Long QTc / 
Ventr. 
Tachycardia/ 
Torsade de Pointe) 
yes yes yes yes yes  yes yes Yes Yes 
initially, 
but repeat 
ECG and 
echo 
normal 
Seizures yes yes yes yes yes yes no yes no 
Movement 
Disorder 
(Ataxia/EPS) 
yes yes yes yes yes yes no mild 
hypertonia 
in all 4 
limbs 
lower 
limb 
stiffness 
Structural 
brain 
abnormalities 
(global brain 
atrophy) 
yes no no no microce-
phalic 
yes not reported not 
reported 
no 
Premature death no yes yes no yes yes no no no 
Lactate (mmol/l) 
(normal<2mmol/l) 
19.9 4.4 3.8 2.1 2,5 2.6 yes 8 no 
Hypo- 
glycemia (mmol/l) 
 
1.11 no no no no no no 0.9 no 
Ketonuria yes yes yes yes yes yes yes yes not 
reported 
Acylcarnitine 
Elevation 
C2  
C10  
C14 
C14:1 
C14:2 
C16:1 
C18:1  
normal normal normal normal C3 
mild 
C14:1 , 
C12-C18  
 
C14, 
C14:1 at 
upper 
limit of 
reference 
range 
normal 
Ammonia (µmol/l) 
(normal 11-32) 
829 121 120 163 not 
reported 
no 55 no not 
reported 
ALT (U/l)  
(normal 7-56) 
12 1931 1536 2810 40 4268 1273 427 ~3000 
AST (U/l) 
(normal 10-40) 
95 3512 3032 2284 40 7326 3211 not 
reported 
~7000 
max. CK ↑ (U/l) 
(normal 22-198) 
10166 261 716 200 000 221 000 419 260 000 >100 000 82 973 >400 000 
TSH (µU/ml) 
(normal 0.4-4) 
6.5 3.7 15.2 17.3 28,6 11.2 33.8 48 not 
reported 
TANGO2 
mutations 
Hom. 
c.262C>T, 
p.Arg88* 
Hemizygous 
c.11_13delTCT, 
p.Phe5del 
Hom. 
c.380+1G>A 
Hom. 
c.220A>C,p
.Thr74Pro 
Hemizygous 
exon 3-9 
deletion 
Hom. 
c.6_9del, 
p.Phe6del 
Hom. 
exon 3-9 
deletion 
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B % of cells with dissambled Golgi appartus/ BFA exposure time (min) 
Min 
CONTROL 
MEAN 
CONTROL 
ERROR 
TANGO2 
MEAN 
TANGO2 
ERROR 
0 0 0 0 0 
3 0 0 0 0 
5 55,4 4,6 33,7 6,4 
10 79,9 0,1 65,5 5,5 
15 98,6 1,4 91 0 
30 100 0 100 0 
60 100 0 100 0 
 
0
50
100
150
0 3 5 10 15 30 60
%
 o
f 
ce
lls
 w
it
h
 d
is
sa
m
b
le
d 
G
o
lg
i a
p
p
ar
at
u
s
BFA exposure time (min)
CONTROL
TANGO2
C
C
O
N
TR
O
L
TA
N
G
O
2
0 105 3015
BFA exposure time (min)A
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MEAN 0 0 55,4 79,9 98,6 100 100
ERROR 0 0 4,6 0,1 1,4 0 0
% of cells with dissambled Golgi apparatus/BFA exposure time (min)
Minutes 0 3 5 10 15 30 60
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Subj. 2.2 0 0 27,3 70,9 91 100 100
MEAN 0 0 33,65 65,45 91 100 100
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